The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model.
about
Prediction of Conversion to Alzheimer's Disease with Longitudinal Measures and Time-To-Event Data.Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid β.From Common to Rare Variants: The Genetic Component of Alzheimer Disease.The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer's disease.EU/US/CTAD Task Force: Lessons Learned from Recent and Current Alzheimer's Prevention Trials.Anti-Amyloid-β Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise.Alzheimer's Disease-Related Dementias Summit 2016: National research priorities.The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset.Tau-based therapies in neurodegeneration: opportunities and challenges.Exploratory trials in mental health: anything to learn from other disciplines?Accelerated long-term forgetting in presymptomatic autosomal dominant Alzheimer's disease: a cross-sectional study.Targeting Alzheimer's Disease at the Right Time and the Right Place: Validation of a Personalized Approach to Diagnosis and Treatment.Resistance vs resilience to Alzheimer disease: Clarifying terminology for preclinical studies.Clinical Trials for Disease-Modifying Therapies in Alzheimer's Disease: A Primer, Lessons Learned, and a Blueprint for the Future.The Role of Genetics in Advancing Precision Medicine for Alzheimer's Disease-A Narrative Review.Master protocol trials in oncology: Review and new trial designsQuestions concerning the role of amyloid-β in the definition, aetiology and diagnosis of Alzheimer's diseaseNeurodegenerative Diseases: Regenerative Mechanisms and Novel Therapeutic ApproachesRare disease registries: potential applications towards impact on development of new drug treatments
P2860
Q33816135-971AB715-6843-4519-B2C9-5D8B049C2E5AQ38933111-DC9B17D0-DAF7-4A02-A564-3733DE56C73AQ39047085-78289914-14E1-4061-9713-8CC89D88505AQ42627792-62C1130B-3398-4155-AF5C-693F35346656Q46211759-7ACD0DAE-0C98-45B3-A390-18522D8E2EE9Q46297382-E0626563-131B-4D91-A8ED-D183BEA895DEQ46391552-C4718EFE-DFAC-4BE7-8BA9-CDDECCA4378EQ47567135-3599FE46-0FF1-401C-96DF-4E6946D05BBAQ47689697-911C3CBF-3301-47C1-A41C-E8F28DFB4AE1Q47832169-142A2468-2A68-4AE9-A887-876463DBD99BQ50138936-2F965982-9F30-4475-931B-C0AC03ECAC4EQ51765788-427CCA63-1302-45DA-BAAC-DDF4E08F42F1Q52625093-DAF5F25E-ADB7-4065-A340-97A4AD86FD8FQ55364364-F8E1E586-62B4-4999-B3F5-A81384807D23Q55381143-167FA34F-4D48-4AD6-9B57-AEE5249F97C0Q57124868-5FAFF86F-4EA0-49B5-9013-47281A988F53Q57800439-8D675791-BF2A-4F18-B31A-73A7A99ABC21Q58737028-43865AA4-846A-4A33-9C5D-85C6B4395772Q58763192-35D210CD-2FCC-4891-9BA3-37E3CBDE4B3D
P2860
The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
The DIAN-TU Next Generation Al ...... and disease progression model.
@en
The DIAN-TU Next Generation Al ...... and disease progression model.
@nl
type
label
The DIAN-TU Next Generation Al ...... and disease progression model.
@en
The DIAN-TU Next Generation Al ...... and disease progression model.
@nl
prefLabel
The DIAN-TU Next Generation Al ...... and disease progression model.
@en
The DIAN-TU Next Generation Al ...... and disease progression model.
@nl
P2093
P2860
P50
P1476
The DIAN-TU Next Generation Al ...... and disease progression model.
@en
P2093
Anna Santacruz
Chengjie Xiong
Cynthia Duggan
DIAN-TU Pharma Consortium for the Dominantly Inherited Alzheimer Network
David B Clifford
Eric M McDade
Guoqiao Wang
Jason Hassenstab
Kathleen Fanning
Katrina Paumier
P2860
P356
10.1016/J.JALZ.2016.07.005
P577
2016-08-29T00:00:00Z